Evidence map›Paper›PMID 40190400›Full record

ArticleFrontiers in endocrinology2025

1,25-dihydroxyvitamin D3 improves non-alcoholic steatohepatitis phenotype in a diet-induced rat model.

Mei Liu, Xiang-Zhun Song, Liu Yang, Yu-Hui Fang, Liu Lan, Jing-Shu Cui, Xiao-Chen Lu, Hai-Yang Zhu, Lin-Hu Quan, Hong-Mei Han

Abstract read
In one paragraph

Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Mei LiuDepartment of Gastroenterology, Affiliated Hospital of Yanbian University, Yanji, Jilin, China.
Xiang-Zhun SongDepartment of Gastroenterology, Jilin Provincial People's Hospital, Changchun, Jilin, China.
Liu YangDepartment of Gastroenterology and Hepatology, Characteristic Medical Center of the Chinese People's Armed Police Force, Tianjin Key Laboratory of Hepatopancreatic Fibrosis and Molecular Diagnosis & Treatment, Tianjin, China.
Yu-Hui FangDepartment of Dermatology, Fuyang People's Hospital of Anhui Medical University, Fuyang, Anhui, China.
Liu LanDepartment of Pathology, Affiliated Hospital of Yanbian University, Yanji, Jilin, China.
Jing-Shu CuiDepartment of Pathology, Affiliated Hospital of Yanbian University, Yanji, Jilin, China.
Xiao-Chen LuDepartment of Gastroenterology, Jimo District People's Hospital, Qingdao, Shandong, China.
Hai-Yang ZhuDepartment of Gastroenterology, Affiliated Hospital of Yanbian University, Yanji, Jilin, China.
Lin-Hu QuanDepartment of College of Pharmacy, Yanbian University, Yanji, Jilin, China.
Hong-Mei HanDepartment of Gastroenterology, Affiliated Hospital of Yanbian University, Yanji, Jilin, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We studied the potential protective effects of 1,25-dihydroxyvitamin D3 (1,25 VD3) supplementation on liver damage induced by a choline-deficient (CD) diet in rats, where impaired liver function leads to decreased 25-hydroxyvitamin D3 levels, the precursor for the active 1,25 VD3. The CD diet reduced serum 25 VD3 levels and increased liver enzymes, indicative of liver damage. Conversely, 1,25 VD3 supplementation alleviated liver damage, reducing liver enzymes and improving histopathological features characteristic of non-alcoholic steatohepatitis (NASH). Oxidative stress and inflammation were mitigated by 1,25 VD3, as evidenced by decreased malondialdehyde and nuclear factor kappa B (NF-κB) expression, and increased total antioxidant capacity (TAOC). 1,25 VD3 also enhanced fatty acid metabolism by increasing peroxisome proliferator-activated receptor alpha (PPARα) and carnitine palmitoyltransferase-1 (CPT-1) expression, promoting lipid transport and oxidation. Additionally, 1,25 VD3 supplementation modulated inflammation by increasing PPARγ expression, reducing NF-κB expression, and decreasing pro-inflammatory cytokines (TNF-α, IL-1β). Anti-inflammatory cytokines (IL-10, IL-4) were increased, and macrophage polarization was shifted towards an anti-inflammatory M2 phenotype. Moreover, 1,25 VD3 upregulated CYP2J3, a cytochrome P450 epoxygenase that converts arachidonic acid to anti-inflammatory epoxyeicosatrienoic acids (EETs) and decreased soluble epoxide hydrolase activity, likely contributing to increased EET levels. Correlation studies revealed positive associations between 1,25 VD3 supplementation, CYP2J3 expression, EETs, as well as negative correlations with NF-κB and TNF-α. PPARα expression positively correlated with TAOC and CPT-1, while PPARγ expression negatively correlated with inflammatory markers. These findings demonstrate the therapeutic potential of 1,25 VD3 in alleviating NASH through regulation of fatty acid metabolism, inflammation, and oxidative stress.

Indexed as

CalcitriolDietNon-alcoholic Fatty Liver DiseaseVitamin DAnimalsCholine DeficiencyDietary SupplementsDisease Models, AnimalInflammationLiverMaleOxidative StressPhenotypeRatsRats, WistarCalcitriolVitamin DCYP450inflammationmacrophagenon-alcoholic steatohepatitisvitamin D3

Identifiers

PMID40190400
PMCPMC11968344

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.